Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
… two JAKi, and another 7% have received three. Drugs used were: upadacitinib (40%), baricitinib (35%), tofacitinib (24%), and filgotinib (11…
…is. 48 (71.6%) were commenced on upadacitinib and 19 (28.4%) on filgotinib. 32 (47.8%) patients were initiated on treatment prior to, and …
…immune-related adverse events (irAEs). Janus kinase inhibitors (JAKi) are a promising steroid-sparing agent for treating corticoster…
…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…
…nitis (n=2), myasthenia gravis (n=1), and sicca syndrome (n=1). JAKi were employed as second-line therapy in 7 patients, third-line …
…Recent studies have indicated that Janus kinase inhibitors (JAKi) exert context-dependent immunomodulatory effects in cancer imm…
…e Janus kinase inhibitors (JAKi), such as baricitinib (BAR) and tofacitinib (TOF), are oral therapeutic options for rheumatoid arthritis (R…
…nt started a b/tsDMARD (abatacept: 242, IL-6Ri: 317, JAKi: 333, rituximab: 176, TNFi: 874). Compared with the wrist, all joints demonstra…
…als (Jan 2021–Sept 2024). Adult CD patients receiving biologics/JAKi were included. Clinical data (Harvey-Bradshaw Index (HBI), CRP,…
…5%) with 29 (25.2%) receiving antihypertensive therapy prior to JAKi treatment. The bivariate analysis revealed that patients with r…